Zhejiang Yongi Technology Co., Ltd., known as YONGTAI TECHNOLOGY, has recently announced a strategic partnership with a major battery manufacturer to supply electrolyte products. This agreement, set to extend through the end of 2026, involves substantial long-term orders and marks a significant development in the company’s business strategy.
YONGTAI TECHNOLOGY, a company based in Taizhou, China, specializes in the research, development, manufacturing, and distribution of fluorine-containing fine chemicals. The company’s product portfolio includes pharmaceuticals for various medical conditions such as heart, cardiovascular, diabetes, central nervous system, anti-infection, and anti-virus. Additionally, YONGTAI TECHNOLOGY produces herbicides, fungicides, and lithium battery materials.
The partnership follows the company’s earlier decision to halt a planned electrolyte production project in Shawan. This decision was driven by changes in market conditions and the need to optimize resource allocation. By aligning with the broader industry trend of shifting from broad capacity expansion to more focused, high-value projects, YONGTAI TECHNOLOGY is positioning itself to strengthen regional supply networks and enhance operational efficiency.
The new agreement is expected to support YONGTAI TECHNOLOGY’s growth objectives and reinforce its position in the battery electrolyte market. This strategic move is in line with the company’s emphasis on reducing exposure to uncertain demand fluctuations while capitalizing on high-value opportunities.
YONGTAI TECHNOLOGY is listed on the Shenzhen Stock Exchange, with a market capitalization of 19,360,000,000 CNY. As of June 16, 2026, the company’s close price was 22.39 CNY, with a 52-week high of 33 CNY on November 17, 2025, and a 52-week low of 11.4 CNY on July 2, 2025. The company’s price-to-earnings ratio stands at 408.88.
For more information about YONGTAI TECHNOLOGY and its products, interested parties can visit the company’s website at www.yongitech.com .
